Emerging Growth Trends Driving Expansion in the Glucagon-like Peptide 1 Market

The glucagon-like peptide 1 (GLP-1) market is on track for significant expansion over the coming years, driven by innovations and rising demand in healthcare. As efforts to manage chronic diseases and obesity intensify worldwide, this sector is becoming increasingly important, with key players and technological advancements shaping its future landscape.

Projected Expansion of the Glucagon-like Peptide 1 Market by 2030
The GLP-1 market is predicted to grow substantially, reaching a market size of $33.26 billion by 2030. This reflects a compound annual growth rate (CAGR) of 8.6% during the forecast period. The growth is fueled by several factors, including the rising need for effective weight management treatments, increased investments in peptide drug development, breakthroughs in oral peptide delivery methods, and a heightened focus on managing chronic illnesses. Additionally, the market benefits from a surge in personalized medicine approaches that tailor therapies to individual patient needs. Key trends expected to influence the market include wider use of GLP-1 therapies for obesity, ongoing development of oral GLP-1 formulations, emphasis on long-acting peptide drugs, the rise of combination therapies, and improvements in patient-centered drug delivery systems.

Download a free sample of the glucagon-like peptide 1 market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10830&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Feb_PR

Leading Players Driving the Glucagon-like Peptide 1 Market Forward
Some of the top companies active in the GLP-1 sector include Novo Nordisk, Eli Lilly and Company, Pfizer Inc., AstraZeneca Plc, Sanofi S.A., Boehringer Ingelheim International GmbH, Merck and Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Johnson and Johnson, Amgen Inc., GlaxoSmithKline Plc, Novartis AG, Bayer AG, AbbVie Inc., Bristol Myers Squibb Company, Biocon Limited, Hanmi Pharmaceutical Co., Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Zealand Pharma A/S, and Gan and Lee Pharmaceuticals Co., Ltd.

In a notable development from March 2024, Novo Holdings A/S, an investment firm based in Denmark, acquired Catalent Inc. for $16.5 billion. This strategic acquisition is aimed at bolstering Novo Holdings' position in the fast-growing GLP-1 market by utilizing Catalent's well-established fill-finish manufacturing capabilities. Catalent, a U.S.-based biotech company, specializes in advanced pharmaceutical delivery technologies and development solutions, providing critical infrastructure to meet the escalating demand for diabetes and weight-loss therapies.

View the full glucagon-like peptide 1 market report:
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Feb_PR

Emerging Trends Transforming the Glucagon-like Peptide 1 Market
Key industry players are increasingly focused on technological innovations that improve the effectiveness, safety, and user-friendliness of GLP-1 therapies, particularly for managing weight and diabetes. GLP-1 treatments are peptide-based injectable drugs designed to mimic the natural hormone GLP-1, which plays a vital role in appetite regulation, glucose metabolism, and body weight control.

For example, in March 2024, Novo Nordisk A/S from Denmark introduced Wegovy, the first-ever once-weekly GLP-1 therapy specifically for weight management. Developed through the STEP Phase 3a clinical trial program, Wegovy has demonstrated a favorable safety profile and is intended to help individuals with obesity achieve and maintain significant weight loss. By offering a convenient weekly dosing schedule, Wegovy enhances patient compliance and meets the growing demand for innovative and effective obesity treatments.

Segments Defining the Global Glucagon-like Peptide 1 Market
The GLP-1 market is segmented into key categories to better understand its structure:

1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, and Other Types
2) By Route of Administration: Oral, Parenteral, and Other Routes
3) By End-Users: Hospitals, Specialty Clinics, and Other End Users

Further breakdown includes product-specific forms:
- Trulicity: Available as injection via pre-filled pen, with dosage options such as 0.75 mg and 1.5 mg
- Ozempic: Injection via pre-filled pen, offered in doses like 0.5 mg and 1 mg
- Victoza: Injection form with dosages including 1.2 mg and 1.8 mg
- Rybelsus: Oral tablets in 3 mg, 7 mg, and 14 mg strengths
- Other Types: Includes experimental formulations, combination drugs with other medications, and alternative delivery methods

This segmentation provides a detailed view of the market landscape, highlighting the variety of products and administration routes that cater to diverse patient needs and healthcare settings.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.